Segment Information

9 Months Ended

Sep. 30, 2020

Segment Reporting [Abstract]

SEGMENT INFORMATION

9. SEGMENT INFORMATION

The Company has determined that it operates in two segments, the sapphire and pharmacy businesses.

Revenue is attributed by geographic region based on ship-to location of the Company's customers. The following table summarizes revenue by geographic region:

	Three months ended September 30,				Nine months ended September 30,
	2020		2019		2020		2019
	(in thousands)				(in thousands)
North America	$	1,014	$	561	$	3,188	$	2,120
Asia		91		14		359		134
Other		13		8		21		18
Total revenue	$	1,118	$	583	$	3,568	$	2,272

The following table summarizes sales by product type:

	Three months ended September 30,				Nine months ended September 30,
	2020		2019		2020		2019
	(in thousands)				(in thousands)
Optical	$	892	$	520	$	3.009	$	2,178
Direct Dose Rx		226		63		559		94
Total revenue	$	1,118	$	583	$	3,568	$	2,272

The following table summarizes assets by geographic region:

	As of September 30,		As of December 31,
	2020		2019
	(in thousands)
North America	$	30,381	$	29,703
Asia		710		5,094
Other		—		4
Total assets	$	31,091	$	34,801

Direct Dose Rx accounted for a loss of approximately $92,000 and $192,000 for the three months ended September 30, 2020 and 2019, respectively, and approximately $287,000 and $277,000 for the nine months ended September 30, 2020 and 2019, respectively. The Company established Direct Dose Rx in May 2019.

Direct Dose Rx assets are currently not material to the consolidated financial information of the Company and therefore there is limited disclosure relating specifically to them.